DAVENPORT & Co LLC Raises Stock Holdings in Becton, Dickinson and Company $BDX

Key Points

• DAVENPORT & Co LLC increased its holdings in Becton, Dickinson and Company by 35.3%, owning approximately 0.19% of the company, valued at about $96 million.
• Other institutional investors also made significant changes to their positions, with Brighton Jones LLC growing its holdings by 98.2% in the fourth quarter.
• Becton, Dickinson and Company reported $3.68 EPS for the last quarter, surpassing estimates and indicating a 10.4% year-over-year revenue growth.

DAVENPORT & Co LLC grew its position in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 35.3% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 558,679 shares of the medical instruments supplier's stock after acquiring an additional 145,804 shares during the period. DAVENPORT & Co LLC owned about 0.19% of Becton, Dickinson and Company worth $96,020,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Brighton Jones LLC grew its holdings in Becton, Dickinson and Company by 98.2% in the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier's stock worth $401,000 after purchasing an additional 877 shares during the period. NBC Securities Inc. purchased a new position in Becton, Dickinson and Company in the first quarter worth about $102,000. Pines Wealth Management LLC grew its position in Becton, Dickinson and Company by 20.9% during the first quarter. Pines Wealth Management LLC now owns 1,425 shares of the medical instruments supplier's stock valued at $326,000 after buying an additional 246 shares during the period. Congress Asset Management Co. raised its holdings in Becton, Dickinson and Company by 7.9% in the 1st quarter. Congress Asset Management Co. now owns 1,892 shares of the medical instruments supplier's stock worth $433,000 after purchasing an additional 139 shares during the period. Finally, Patriot Financial Group Insurance Agency LLC raised its stake in shares of Becton, Dickinson and Company by 127.7% in the first quarter. Patriot Financial Group Insurance Agency LLC now owns 11,414 shares of the medical instruments supplier's stock worth $2,615,000 after buying an additional 6,401 shares during the period. Institutional investors own 86.97% of the company's stock.

Insider Buying and Selling at Becton, Dickinson and Company

In related news, EVP Michael David Garrison sold 1,185 shares of Becton, Dickinson and Company stock in a transaction that occurred on Friday, July 18th. The shares were sold at an average price of $180.29, for a total value of $213,643.65. Following the completion of the transaction, the executive vice president owned 4,887 shares in the company, valued at approximately $881,077.23. The trade was a 19.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Claire Fraser sold 917 shares of the company's stock in a transaction that occurred on Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total transaction of $171,937.50. Following the sale, the director owned 22,226 shares in the company, valued at $4,167,375. The trade was a 3.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 3,023 shares of company stock worth $562,036 in the last quarter. Company insiders own 0.36% of the company's stock.

Becton, Dickinson and Company Stock Up 1.1%

BDX stock opened at $193.67 on Monday. The firm's fifty day simple moving average is $189.03 and its 200-day simple moving average is $187.06. The company has a market capitalization of $55.51 billion, a P/E ratio of 34.83, a price-to-earnings-growth ratio of 1.51 and a beta of 0.25. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.10 and a quick ratio of 0.62. Becton, Dickinson and Company has a 12 month low of $163.33 and a 12 month high of $251.99.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.40 by $0.28. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The business had revenue of $5.51 billion for the quarter, compared to analyst estimates of $5.50 billion. During the same period in the prior year, the company posted $3.50 EPS. The company's revenue for the quarter was up 10.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. As a group, equities research analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 30th. Investors of record on Monday, September 8th were issued a $1.04 dividend. This represents a $4.16 annualized dividend and a yield of 2.1%. The ex-dividend date was Monday, September 8th. Becton, Dickinson and Company's dividend payout ratio (DPR) is 74.82%.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on BDX. Wells Fargo & Company boosted their price objective on Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an "equal weight" rating in a research report on Friday, August 8th. Wall Street Zen raised Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research note on Saturday, August 9th. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Becton, Dickinson and Company in a research note on Saturday, September 27th. Royal Bank Of Canada initiated coverage on Becton, Dickinson and Company in a research report on Thursday, September 25th. They issued a "sector perform" rating and a $211.00 price objective on the stock. Finally, Morgan Stanley lifted their price target on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an "overweight" rating in a research note on Monday, August 11th. Three research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat, Becton, Dickinson and Company currently has a consensus rating of "Hold" and an average price target of $205.40.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.